RxDoctor Payments DataLook up a doctor →

Steven Baumgarten, MD

Critical Care Medicine · Cherry Hill, NJNPI 1528038114

Payments from drug & device makers

$8,745in general payments, 2019–2025

Across 532 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Mylan Specialty L.p.$512
  • Sanofi$491
  • Boehringer Ingelheim$350
  • Regeneron Healthcare Solutions, Inc.$344
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,726100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,745 in reported general payments places this provider in the 85th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$219,615
Medicare patients
708
Services billed
1,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter446$391,561
EsbrietPirfenidone12$128,352
Dupixent PenDupilumab24$108,304
Breo ElliptaFluticasone/Vilanterol164$82,653
Breztri AerosphereBudesonide/Glycopyr/Formoterol76$52,801
EliquisApixaban79$47,327
Incruse ElliptaUmeclidinium Bromide91$40,989
NucalaMepolizumab11$38,143
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$37,696
Pirfenidone11$31,094
Fluticasone-SalmeterolFluticasone Propion/Salmeterol183$21,648
Spiriva RespimatTiotropium Bromide28$16,936
Albuterol Sulfate HfaAlbuterol Sulfate400$13,894
Combivent RespimatIpratropium/Albuterol Sulfate12$13,211
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$12,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Nucala, Anoro Ellipta$1,987$593,422777 claims
Genentech USA, Inc.Esbriet$93$128,35212 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,116$61,723107 claims
PfizerEliquis$29$47,32779 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$350$42,23560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 critical care medicine providers in New Jersey.

Other critical care medicine in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →